Prevalence, clinical and biochemical profile of subclinical hypothyroidism in normal population in Mumbai

Vaishali Deshmukh, Anish Behl, Vagesh Iyer, Harish Joshi, Jayashree P. Dholye, Prema K. Varthakavi

Department of Endocrinology, B.Y.L. Nair Hospital, Mumbai, India

ABSTRACT

Background: Subclinical Hypothyroidism (ScHt) affects 3–15% of the adult population. Its clinical and biochemical profile is not well defined, especially in Indian scenario. Our study aimed at screening normal population to define normative ranges of thyroid hormones and Serum thyroid stimulating hormone (S.TSH) and prevalence of ScHt and thyroid autoimmunity.

Materials and Methods: Two-hundred thirty-seven normal subjects without family history of thyroid disease were evaluated for symptoms and laboratory tests for thyroid dysfunction and autoimmunity. Results: The thyroid function tests were as follows: Euthyroid Group: Mean values were: T3: 1.79 ± 0.42 ng/mL, T4: 10.23 ± 2.25 µg/dL, FT3: 1.88 ± 0.19 pg/mL, FT4: 1.12 ± 0.21 ng/dL, S.TSH: 2.22 ± 1.06 µlu/mL. 10.2% of euthyroid subjects had antimicrosomal antibodies (AMA) +ve (mean titer 1:918) and 23.6% were anti-thyroid peroxidase autoantibody (anti-TPO) +ve (mean titer 15.06 Au/mL). The euthyroid outlier range for S.TSH was 0.3–4.6 µlu/mL. The values were comparable in both the sexes. Those with S.TSH ≥ 5 µlu/mL were defined to have ScHt. ScHt Group: Prevalence of ScHt was 11.3% (M:F ratio 1:3.7). 74% belonged to 35–54 years age group and prevalence increased with age (post-menopausal females: prevalence 20%). S.TSH was 9.8 ± 7.22 µlu/mL, mean S.AMA was 1:5079 (40.7% positivity) and mean S.anti-TPO was 260 Au/mL (47.6% positivity). Majority were agoitrous (74%), and stage I goiter was seen in 26% of this population. Symptom score of 5–8 was seen in 55% ScHt subjects versus 35% normal subjects. Conclusion: Mean S.TSH in our population was 2.22 µlu/mL (euthyroid outliers: 0.3–4.6 µlu/mL); hence, S.TSH above 4.6 µlu/mL should be considered as abnormal. The prevalence of thyroid autoimmunity increases after age of 35 years. ScHt presents mainly in agoitrous form and with positive antibodies, suggesting autoimmunity as the cause.

Key words: Autoimmunity, normative ranges, prevalence, subclinical hypothyroidism

INTRODUCTION

Subclinical hypothyroidism (ScHt) is defined as high S.TSH concentration with normal serum Free Thyroxine (FT₄) and Free Triiodothyronine (FT₃) concentrations, associated with few or no signs and symptoms of hypothyroidism.[1] Subclinical hypothyroidism is the most prevalent thyroid disorder affecting 3–15% of the adult population. Its incidence increases with advanced age,[3,5] female gender,[4,6] and greater dietary iodine intake.[7–10]

Various studies have shown that ScHt is associated with hyperlipidemia,[3,5,10–14] neuromuscular,[15–17] and neuropsychiatric symptoms,[15–17] myocardial dysfunction,[18–21] and decrease in quality of life with progression to overt hypothyroidism.[8,10,13]

Due to apparently asymptomatic nature of the illness, the “American Thyroid Association’(ATA) has recommended routine population screening of both sexes at age 35 years and then every 5 years thereafter for early detection and treatment of ScHt. There is paucity of Indian data on prevalence, clinical profile, biochemical profile and therapy of this condition. There are no Indian guidelines for screening of high-risk population for ScHt. This study attempts to determine the normal thyroid hormone
ranges in Indian population and to find an answer to issues regarding the prevalence and biochemical and clinical features of ScHt, which can help in early diagnosis.

**AIMS AND OBJECTIVES**

1. To define the normal ranges for thyroid hormones and S.TSH.
2. To study the prevalence of ScHt in paramedical population of a public hospital in Mumbai.
3. To study association of S.TSH with goiter and thyroid autoimmunity in this population.

**MATERIALS AND METHODS**

**Study design**
A cross-sectional observational study was conducted in the Endocrinology Department of a Municipal Charitable hospital in Mumbai. Two-hundred thirty-seven subjects from paramedical personnel registry were selected for the same. The study was conducted after being approved by the Institutional Ethics Committee.

**Sample size calculation**
Sample size was based on the formula “sample size = n/1 - n/population” as per which 196 subjects were required to be screened to achieve a level of confidence of 99.99%. Volunteers were selected by stratified random multistage sampling using random number table. Every 7th “healthy person” from the registry was invited to participate into the study. Sample was stratified based on gender (207 females and 30 males) as ScHt is reported to be more prevalent in females.[4]

**Volunteer selection**
Subjects ≥ 18 years of age of both sexes and those who consented to participate and take screening tests in the protocol were included in the study. Subjects with known current or past thyroid disorders, pregnant females and subjects with any known illnesses or on chronic medications were excluded from the study.

**Statistical considerations**
Statistical analysis of the data was performed by SPSS statistical software (version 10.1). Chi-square test was used to test the significance of association in cases of qualitative data, unpaired ‘t’ test was used to test the significance of association in case of quantitative data between two separate groups, while paired ‘t’ test was used to test the significance of association in case of paired quantitative data amongst individual groups. Pearson’s correlation coefficient (r) was used to assess the correlation of S.TSH with qualitative data and Spearman’s correlation coefficient (rho) was used to assess the correlation of S.TSH with qualitative data. P values > 0.05 were not significant and values ≤ 0.05 were significant.

**Methods**
The volunteers were evaluated by a detailed history and clinical examination for evaluation of thyroid disease based on proforma designed for the same. Symptom questionnaire, which involved questions regarding various clinical features of thyroid dysfunction, was used such that 1 point was awarded to every symptom present and then all points were added to obtain the symptom score. Goiter staging was done based on the PAHO staging into 4 grades (0–III).

**Assay methodology**
Laboratory tests for thyroid function tests (serum levels of T₁, T₂, FT₁, FT₂, and S.TSH) and serum thyroid autoantibody titers (antimicrosomal antibodies [S.AMA], and anti-thyroid peroxidase autoantibody [S.anti-TPO]) were evaluated in these subjects.

Total T₁ and T₂ were determined by standard double antibody radioimmunoassay technique, supplied by BRIT Mumbai. Sensitivities of these tests were 0.24 ng/mL and 0.5 ng/mL, respectively. Free T3 (FT₁) and Free T4 (FT₂) were determined by direct one-step radioimmunoassay using gamma coat free T₁ ¹²⁵I and free T₂ ¹²⁵I RIA kit supplied by Diasorin, USA. Sensitivities of these tests were 0.05 pg/mL and 0.07 ng/dL, respectively. S.TSH was determined by 2-site immunoradiometric assay (IRMA) using kit supplied by BRIT Mumbai. Its sensitivity was 0.025 µlu/mL. S.AMA was tested using Serodia-AMC reagent. Positive reaction at any dilution (≥ 1:400) was taken as a reactive test. S.anti-TPO antibodies were determined by two staged IRMA assay using AB-TPOK-3 kit supplied by Diasorin, USA. S.anti-TPO was positive when values were > 15 AU/mL. Sensitivity of this reaction was < 1 AU/mL.

**Observations**
Figure 1, Table 1 and Figure 2, Table 2 and Figure 3.

**DISCUSSION**
Screening studies to assess thyroid disorder prevalence have provided valuable insights in understanding the epidemiology of all thyroid disorders in the population worldwide. There is a rise in the prevalence of all the thyroid disorders including ScHt in India post iodization era. However, screening studies have been a rarity in India and there is scanty literature on prevalence of these disorders in all regions of India. Our study has shown...
Table 1: The thyroid function tests in screened normal population

| KIT range | Euthyroid population | ScHt patients |
|-----------|----------------------|--------------|
|           | Range                | Mean ± SD    | Range                | Mean ± SD    |
| S.T3 (ng/mL) | 0.7–2.0 ng/mL        | 0.7–5       | 1.2–2.3              | 1.77 ± 0.31  |
| S.T4 (µg/dL) | 5.5–13.5 µg/dL       | 4.4–17.4    | 6.1–15.3             | 9.75 ± 0.53  |
| S.FT3 (µg/mL) | 1.5–5 µg/mL         | 1.6–2.1     | 0.71–2.4             | 1.71 ± 0.45  |
| S.FT4 (ng/mL) | 0.95–2.23 ng/mL      | 0.68–1.8    | 0.69–2.0             | 1.18 ± 0.30  |
| S.TSH (µIU/mL) | 0.17–4.05 µIU/mL  | 0.3–4.6     | 5–31                 | 9.82 ± 7.26  |
| S.anti TPO (Au/mL) | Positive > 15 Au/mL | 1.2–190.6   | 2.1–1249.9            | 260 ± 424.06 |
| S.AMA titer | Reactive – positive at dilution ≥ 1:400 | 1:100–1:25600 | 1:918.96            | 1:100–1:102400 | 1:5079.68 |

The euthyroid outlier range for S.TSH was 0.3 to 4.6 µIU/mL. Of the studied population 11.3% subjects had ScHt; 1.6% had overt hypothyroidism; 0.4% had overt hyperthyroidism; while none had subclinical hyperthyroidism. The prevalence of ScHt in postmenopausal women was 19.6%. The male: female ratio was 1:3.7. Age distribution and its association with S.TSH of the screened population was as shown in Figure 1.

Table 2: Serum thyroid stimulating hormone levels and thyroid autoimmunity

| S.TSH (µIU/mL) | S.AMA | S.anti-TPO |
|---------------|-------|-----------|
|<5.0          | 184 (89.7) | 42 (76.4) |
|> 5.0         | 16 (59.2)  | 11 (52.4) |
| Total         | 200 (100)  | 53 (70)   |

S.AMA and S.anti-TPO positivity was maximum in age group 35–54 years. Goiter prevalence was independent of thyroid autoimmunity, 11% of AMA positive and 28.8% of anti-TPO positive subjects were agogous. We assayed anti-TPO antibodies in 76 subjects. 3.7% anti-TPO negative subjects were AMA positive while 19% subjects with AMA negative were anti-TPO positive.

Symptom score: 55.6% patients with ScHt had a symptom score between 5 and 8 (based upon the symptom questionnaire where each symptom was awarded 1 point). Commonest symptoms were physical fatigue (69%), lethargy (63%), weight gain (62%), dry hair/alopecia (55%), myalgia/arthralgia (49%), memory loss (48%) and paresthesia (46%) and were significantly higher than the euthyroid population. So, ScHt may not be literally subclinical but may harbor subtle symptoms, which can easily be mistaken for symptoms of menopause.

Figure 1: Prevalence of ScHt showed a rising trend after age of 35 years.

Figure 2: Most of the ScHt patients had no goiter or stage 1 goiter. However, 9% of euthyroid subjects had stage II or III goiter.

Figure 3: Comparison of symptoms between euthyroid population and ScHt patients revealed following data.
that ScHt was the most prevalent thyroid disorder in the study population followed by overt hypothyroidism and hyperthyroidism. This prevalence of ScHt is comparable to the large epidemiologic studies, viz: Framingham, Rotterdam and Colorado studies [Table 3].

The prevalence of ScHt in our population was higher than the Wickham survey, probably because our S.TSH cut off was lower at 5 µIU/mL and our study population was older. Besides our study population composed of select paramedical staff population while Wickham survey was done on a community basis. The prevalence of ScHt differed in all above studies because the criteria for age and S.TSH cut off ranges were variable. 74% subjects with ScHt belonged to the age group 35–54 years and prevalence showed rising trend with age. This age-wise increase in prevalence is probably due to thyroid autoimmunity, which is known to increase with age as reported in the Wickham survey.[1] Besides, prevalence was more in females and increased with age, which is similar to that observed by Parle et al.[21] Prevalence was also more in postmenopausal women.

The population S.TSH range correlated with normal kit range, T₃ and T₄ ranges were higher, while FT₃ and FT₄ were lower than normal kit range. This may be due to excess protein binding affinity of thyroid binding globulin in study population.

S.TSH levels inversely correlated with goiter, implying that ScHt may be present without goiter, which was similarly found in the Wickham survey.[1] This is probably related to the rapid progression of the autoimmune disorder leading to early thyroid gland atrophy, also implying that subclinical autoimmune thyroiditis may manifest initially as goiter but with progression the thyroid gland atrophies, causing ScHt. Thyroid autoantibody positivity was maximum in age group 35–54 years. S.AMA and S.anti-TPO antibodies correlated well with each other and with S.TSH. High S.TSH positively correlated with antibody positive status and was also associated with a higher symptom score, weight gain, physical fatigue and alopecia being the commonest of symptoms.

**Prevalence studies in India**

Family studies conducted in Mumbai by Dr Meena Desai et al. on first-degree relatives of children with thyroiditis revealed presence of AMA in 43% and thyroid disease in 26%,[22] Among 71 index cases, overt hypothyroidism was seen in 17% and subclinical hypothyroidism in 32%. Siblings had a 23% incidence of subclinical hypothyroidism and no overt cases were reported.

In an another study done by Marwaha RK, Tandon N, Kochupillai N et al. on countrywide screening of goitrous healthy young girls in India, it was seen that in patients with FNAC-proven juvenile autoimmune thyroiditis, subclinical hypothyroidism was seen in 15% cases.[24]

Various other epidemiological studies in India mentioned in the [Table 4] have shown a prevalence rate varying between 9 and 11.4%, which is similar to that seen in our study.

**Conclusions**

Normative data of thyroid functions needs to be established separately for each individual population. Any S.TSH value above 4.6 microIU/mL needs to be considered as abnormal in reference to the diagnosis of ScHt. Screening for ScHt needs to be considered in peri-menopausal females in view of high prevalence of raised S.TSH and thyroid autoimmunity as seen in our study population after the age of 35 years. In our study, ScHt presented mainly in the goitrous form and was associated with significant comorbidity in form of lethargy, fatigue, and weight gain which is mostly undiagnosed or neglected in peri-menopausal population. Thus, any subject presenting with undiagnosed fatigue and weight gain needs to be screened for presence of ScHt.

Our study provides valuable inputs to help define normative data of thyroid function in Indian population.

---

**Table 3: International epidemiological studies**

| Place of study | Reference | Age (in years) | Sex (%) | Number | Prevalence % | TSH Cut off (µIU/mL) |
|----------------|-----------|----------------|---------|--------|--------------|----------------------|
| Wickham        | Tunbridge et al.[8] | 18+    | 33    | 77   | 2779                | 8.9                 | 2.8                | 7.5                | > 6 |
| Sweden         | Nystrom et al.[23] (1981) | 44+    | 0    | 100  | 1283                | 5.1                 | -                 | 5.1                | > 8 |
| Farmingham     | Sawin et al.[24] | 60+  | 41   | 59   | 2139                | 10.3                | 5.6               | 13.5               | > 5 |
| Birmingham     | Parle et al.[24] (1990) | 60+    | 41   | 59   | 1210                | 8.3                 | 2.9               | 11.6               | > 5 |
| U.S.A.         | Bauer et al.[25] (1998) | 65+    | 0    | 100  | 279                 | 6.8                 | -                 | 6.8                | >5.5 |
| Rotterdam      | A.E. Hak et al.[19] (2000) | 55+    | 0    | 100  | 1149                | 10.8                | -                 | 10.8               | > 4.0 |
| U.S.A.         | Canaris et al.[26] | 70-79 | 49   | 51   | 2799                | 3.9                 | -                 | 11.1               | > 5.5 |
| Colorado       | Kanaya et al.[19] (2002) | 18+    | 44   | 56   | 2336                | 9.5                 | -                 | -                  | > 5.1 |
| Mumbai         | Present study (2003) | 20-60 | 13   | 87   | 237                 | 11.3                | 3.3               | 12.5               | > 5 |

---

Indian Journal of Endocrinology and Metabolism / May-Jun 2013 / Vol 17 | Issue 3
and epidemiology of subclinical hypothyroidism in India and improving our understanding of the same.

**Limitations**

Screening for ScHt should ideally be performed in community population, but due to lack of feasibility we have screened our hospital paramedical staff and extrapolated this data to the community. Small number of male participants in this study precludes any conclusion for screening guidelines in male subjects in this age group.

**Acknowledgments**

We duly thank: Dr Kasbe for the statistical analyses; Dr Varun Oak for drafting this article; and Mrs. Sengupta and Mrs Merchant for their lab assistance.

**References**

1. Douglas S. Ross subclinical hypothyroidism. In: Braverman LE, Utiger RD, editors. Werner and Ingbar's The Thyroid: A fundamental and clinical text. 8th ed. Philadelphia: Lippincott Williams and Wilkins; 2000. p. 1001-6.

2. Ayala AR, Danese MD, Ladenson PW. When to treat mild hypothyroidism. Endocrinol Metab Clin N Am 2000;29:399-415.

3. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community. The Wickham survey. Clin Endocrinol (Oxf) 1977;7:481-93.

4. Sawin CT, Castelli WP, Hershman JM, McNamara P, Bacharach P. The aging thyroid. Thyroid deficiency in Farmingham study. Arch Intern Med 1985;145:1396-88.

5. Geul IW, van Sluisveld JL, Grobbee DE, Docter R, de Bruyn AM, Hooykaas H, et al. The importance of thyroid microsomal antibodies in development of elevated serum TSH in middle age women; Association with serum lipids. Clin Endocrinol (Oxf) 1993;39:275-80.

6. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in community. A 20 year follow up of the Wickham survey. Clin Endocrinol 1995;43:55-68.

7. Aghini-Lombardi F, Antonangeli L, Martino E, Vitti P, Maccherini D, Leoli F, et al. The spectrum of thyroid disorders in iodine deficient community. The Pescopagano Survey. J Clin Endocrinol Metab 1999;84:561-6.

8. Konno N, Makita H, Yuri K, Iizuka N, Kawasaki K. Association between dietary iodine intake and prevalence of Subclinical Hypothyroidism in coastal regions of Japan. J Clin Endocrinol Metab 1994;78:393-7.

9. Szavolcs I, Podoba J, Feldkamp J, Dohan O, Farkas I, Saigó M, et al. Comparative screening for thyroid disorders in older age in areas of iodine deficiency, long term iodine deficiency, long term iodine prophylaxis and abundant iodine intake. Clin Endocrinol (Oxf) 1997;47:87-92.

10. Kung AW, Janus ED. Thyroid dysfunction in ambulatory elderly Chinese subjects in an area of borderline iodine intake. Thyroid 1996;6:111-4.

11. Staub J, Althaus BU, Engel H, Ryff AS, Trabucco P, Marquardt K, et al. Spectrum of subclinical and overt hypothyroidism. Effect on thyroidoprotein, proactin and thyroid reserve and metabolic impact on peripheral target tissues. Am J Med 1992;92:631-42.

12. Hak AE, Pols HA, Vasser TJ, Deethage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000;132:270-8.

13. Althaus BU, Staub JJ, Ryff-deleche A, Oberhänslis A, Stähelin HB. LDL/HDL- changes in subclinical hypothyroidism: Possible risk factors for coronary heart disease. Clin Endocrinol (Oxf) 1988; 28:157-63.

14. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado disease prevalence study. Arch Intern Med 2000;160:526-34.

15. Misunanas A, Niepomnissche H, Ravera B, Faraj G, Faure E. Peripheral neuropathy in Subclinical Hypothyroidism. Thyroid 1995; 5:283-8.

16. Ozata M, Ozkardes A, Corakci A, Gundogan MA. Subclinical hypothyroidism does not lead to alterations either in peripheral nerves or in BAEPs. Thyroid 1995;5:201-5.

17. Goulios DG, Trimiris N, Delaroudis S, Maltas B, Tzoi M, Daglias A, et al. Stapedial reflex a biological index found abnormal in subclinical hypothyroidism. Thyroid 1998;8:583-7.

18. Kanaya AM, Harris F, Volpato S, Perez-Stable JJ, Harris T, BauerDC. Association between thyroid dysfunction and total cholesterol level in an older biracial population: the health, aging and body composition study. Arch Intern Med. 2002;162:773-9.

19. Ridgway EC, Cooper DS, Walker H, Rodbard D, Malloof F. Peripheral responses to thyroid hormone before and after L-Thyroxine therapy in patients with Subclinical Hypothyroidism. J Clin Endocrinol Metab 1981;53:1238-41.

20. Monzani F, Bello BD, Caracce N, Bertini A, Giorio D, Giusti C, et al. Effect of L thyroxine on cardiac function and structure. In Subclinical hypothyroidism: A double blind placebo controlled study. J Clin Endocrinol Metab 2001;86:1110-5.

21. Bell GM, Todd WT, Forfar GC, Martyn C, Wathen CJ, Gow S, et al. End organ responses to thyroxine therapy in Subclinical Hypothyroidism. Clin Endocrinol (Oxf) 1985;22:83-9.

22. Nyström E, Bengtsson C, Lindquist O, Noppa H, Lindstedt G, Lundberg PA. Thyroid disease and high concentration of serum thyrotrophin in a population sample of women. A 4-year follow-up. Acta Med Scand. 1981;210:39-46.

23. Bauer DC, Ettinger B, Browner WS. Thyroid functions and serum lipids in older women: A population-based study. Am J Med 1998;104:546-51.

24. Parle JV, Franklyn JA, Cross KW, Jones SC, Sheppard MC. Prevalence and follow up of abnormal thyrotropin (TSH) concentration in the elderly in the United Kingdom. Clin Endocrinol (Oxf) 1991; 34:77-83.

25. Desai PM. Disorders of the Thyroid Gland in India. Indian J Pediatr 1997;64:11-20.

26. Marwaha RK, Tandon N, Karak AK, Gupta N, Verma K,
Deshmukh, et al.: Subclinical hypothyroidism in Mumbai

Kochupillai N. Hashimoto thyroiditis: Countrywide screening of goitrous healthy young girls in postiodization phase in India. J Clin Endocrinol Metab 2000;85:3798-802.

27. Unnikrishnan AG, Menon UV. Thyroid disorders in India: An epidemiological perspective. Indian J Endocr Metab 2011; 15:78-81.

28. Rohil V, Mishra AK, Shrewastawa MK, Mehta KD, Lamsal M, Baral N, Majhi S. Subclinical hypothyroidism in eastern Nepal: A hospital based study. Kathmandu Univ Med J 2010; 8:231-7.

29. Sahu MT, Das V, Mittal S, Agarwal A, Sahu M. Overt and subclinical thyroid dysfunction among Indian pregnant women and its effect on maternal and fetal outcome. Arch Gynaecol Obstet 2010; 281:215-20.

30. Brahmbhatt SR, Fearnley R, Brahmbhatt RM, Eastman CJ, Boyages SC. Study of biochemical prevalence indicators for the assessment of iodine deficiency disorders in adults at field conditions in Gujarat (India). Asia Pac J Clin Nutr 2001; 10:51-7.

31. Abraham R, Murugan VS, Pukazhvanthen P, Sen SK. Thyroid disorders in women of Puducherry. Indian J Clin Biochem 2009; 24:52-9.

Cite this article as: Deshmukh V, Behl A, Iyer V, Joshi H, Dholye JP, Varthakavi PK. Prevalence, clinical and biochemical profile of subclinical hypothyroidism in normal population in Mumbai. Indian J Endocr Metab 2013; 17:454-9.

Source of Support: In the Form of Grants: Nair Golden Jubilee Research Foundation. Conflicts of Interest: No.

Staying in touch with the journal

1) Table of Contents (TOC) email alert
   Receive an email alert containing the TOC when a new complete issue of the journal is made available online. To register for TOC alerts go to www.ijem.in/signup.asp.

2) RSS feeds
   Really Simple Syndication (RSS) helps you to get alerts on new publication right on your desktop without going to the journal’s website. You need a software (e.g. RSSReader, Feed Demon, FeedReader, My Yahoo!, NewsGator and NewsCrawler) to get advantage of this tool. RSS feeds can also be read through FireFox or Microsoft Outlook 2007. Once any of these small (and mostly free) software is installed, add www.ijem.in/rssfeed.asp as one of the feeds.